Aminat Bello

Although the development of anti-HER2 treatments has come a long way, the likelihood of acquired resistance remains high. According to a study published in Therapeutic Advances in Medical Oncology, new treatment options and combinations can…

HER2-positive breast cancer provides many distinct therapeutic challenges, and these can be simplified through a comprehensive understanding of the molecular subtypes characterizing different forms of heterogeneity that this cancer may exhibit. As heterogeneity is one…

A trial of endocrine therapy after breast-conserving surgery will aid in patient treatment decisions regarding the choice of adjuvant therapy. Among the large number of women that are diagnosed with breast cancer each year, many…

This review examined the disparities in cancer incidence and outcomes in the United States of America by race and ethnicity. Health disparities are known to result from biological factors, as well as social determinants of…

More than a 60-day delay in chemotherapy, after the diagnosis of breast cancer, results in 26% increased risk of death for the patient. Medical experts sought to better understand why many female patients choose to…

Gene mutations are a critical element in younger patients, >40 years of age, who are at high risk for breast carcinomas and additional malignancies. Studies have been conducted to determine the precise genetic mutations associated…

Breast Conservation Surgery (BCS) is a common response to a variety of breast cancer diagnoses. This surgery can involve either a partial mastectomy procedure or oncoplastic surgery. This study involves an analysis of the racial…

A recent study led by Dr. Neha Goel at the University of Miami analyzed how race/ethnicity and zip code affect breast cancer survival in America. Specifically, the study used a measure known as the index…

A research study led by Mary Smith, J.D., M.B.A. of the Research Advocacy Network in Plano, Texas, supports the inclusion of patient and consumer perspectives in the design of chemotherapy de-escalation clinical trials. The study…

A research study led by Dr. Paolo Nuciforo at the Vall d’Hebron Institute of Oncology, Molecular Oncology in Barcelona, Spain, supports using pathologic complete response (pCR) to guide early-stage HER2+ breast cancer treatment. The study,…